Company |
Product |
Description |
Indication |
Status (Date) |
|
||||
CANCER | ||||
|
||||
Atrix Labora- |
Leuprogel One-Month Depot |
Leuprolide acetate |
Prostate cancer |
Companies submitted a market authorization application in Germany (12/4) |
|
||||
Ligand Pharma- |
Onzar |
Denileukin diftitox |
Cutaneous T-cell lymphoma |
Company submitted a regulatory application to market Onzar in Europe (12/19) |
|
||||
Novogen |
Phenoxodiol |
Small molecular signal transduction inhibitor designed to target abnormal signaling processes in cells |
Leukemia |
Company began a Phase Ib/IIa trial in Australia (12/18) |
|
||||
Orphan |
Busulfex |
Busulfan |
Leukemia, lymphoma and myelodysplastic syndrome |
Company gained approval of Busulfex in South Korea in combination with cyclophosphamide to treat certain leukemias, lymphoma and myelodysplastic syndrome (12/3) |
|
||||
Valentis Inc. |
IL-2 Gene- |
Plasmid encoding the human interleukin-2 gene and a cationic lipid gene-delivery system |
Head and neck cancer |
Phase IIb test results were poor showing the product didn't work at the tested dose in this indication; the trial was conducted in Germany, the Czech Republic and Russia (12/3) |
|
||||
CARDIOVASCULAR | ||||
|
||||
Actelion Ltd. |
Tracleer |
Bosentan tablets |
Pulmonary arterial hypertension |
The Canadian Health Authority approved Tracleer (12/3) |
|
||||
GlycoDesign |
GH9001 |
Antithrombotic drug candidate |
Thrombosis |
Companies initiated a Phase I trial in the UK (12/20) |
|
||||
Transkaryotic |
Dynepo |
Epoetin delta; human erythropoietin |
Anemia associated with renal disease |
A European evaluation committee issued a positive opinion recommending approval (12/12) |
|
||||
INFECTION | ||||
|
||||
Cangene Corp. |
|
Anti-hepatitis B hyperimmune |
Hepatitis B |
Company filed a new drug submission in Canada (12/18) |
|
||||
MISCELLANEOUS | ||||
|
||||
Paladin Labs |
Antizol |
Fomepizole injection |
Methanol poisoning |
Antizol was approved in Canada (12/5) |
| ||||
Transgene SA |
MVA- |
Vaccine |
Vulvar intraepithelial neoplasia |
Company initiated a Phase II trial in France (12/18) |
|
||||
Notes: | ||||
Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market. | ||||
TSE = Toronto Stock Exchange; SWX = Swiss Stock Exchange |
